Vishenary, LLC
Publicly observedHockessin, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Hockessin | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Vishenary, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MG9DA3QB9YC1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant23 Sept 2025Publicly observed
NIH SBIR/STTR award: A novel Th17-enhancing adjuvant and conserved antigen for protection against viral/bacterial co-infection
USD 283,001.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant23 Sept 2025Publicly observed
NIH SBIR/STTR award: A novel Th17-enhancing adjuvant and conserved antigen for protection against viral/bacterial co-infection
USD 308,669.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.